Sabril (SAY-bril, vigabatrin) is a new oral therapy for refractory epilepsy and infantile spasms

October 2009

Sabril (SAY-bril, vigabatrin) is a new oral therapy for refractory epilepsy and infantile spasms.

Use of this drug will be restricted because it can cause permanent vision loss in about 30% of patients.

This vision loss is a progressive narrowing of the visual field. The risk increases with higher doses or longer duration.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote